Alvotech (ALVO) 株式分析

企業概要

Alvotech is a biosimilar medicine developer and manufacturer that serves patients globally across therapeutic areas including autoimmune conditions, eye disorders, bone diseases, and cancer. Within the broader Healthcare sector, the company specifically operates in the Drug Manufacturers - Specialty & Generic industry, focusing on the production of high-concentration, low-volume adalimumab formulas such as AVT02. The enterprise holds a market capitalization of $1.12B and generated annual revenue (TTM) of $588.90M while employing a workforce of 1279 individuals. These financial figures indicate that Alvotech occupies a mid-cap position within the specialized pharmaceutical market, possessing sufficient scale to fund its R&D pipeline and manufacturing operations without yet reaching the valuation thresholds of large-cap biotechnology giants. The combination of its specific product focus and current market size suggests a company in a growth phase where revenue generation is critical for sustaining its specialized manufacturing capabilities.

財務健全性

The company reported a revenue (TTM) of $588.90M with a net income (TTM) of $27.92M and an EBITDA of $103.98M. The significant disparity between the $588.90M revenue and the $27.92M net income reveals a substantial cost structure consisting of high operating expenses, likely driven by research and development costs and manufacturing overhead typical of the specialty drug industry. Alvotech generated free cash flow of $24.60M, which provides a measure of financial flexibility allowing the firm to fund capital expenditures and working capital needs without relying solely on external financing. The gross margin stands at 60.0%, indicating strong pricing power and efficient production costs relative to the cost of goods sold for biosimilars. The operating margin of 33.8% and profit margin of 4.7% further demonstrate that while the company retains a significant portion of revenue after direct costs, the final bottom-line profitability is compressed by substantial general and administrative or R&D expenditures. In terms of leverage, the company holds $172.36M in cash against $1.45B in debt, while the debt-to-equity ratio is not available, suggesting a capital structure that may rely heavily on equity or complex debt instruments common in biotech. The current ratio of 1.89 indicates a conservative approach to short-term liquidity, as current assets are nearly double current liabilities, providing a comfortable buffer against short-term obligations. Regarding return metrics, the return on assets is 3.8%, while return on equity is not available; these figures suggest that management is utilizing assets to generate modest returns, which is typical for capital-intensive industries before achieving significant profitability milestones.

バリュエーション評価

The trailing twelve-month P/E ratio is 36.00, while the forward P/E is 19.68. This substantial difference between the trailing and forward multiples implies that the market expects a significant increase in earnings in the future to bring the valuation down to a more normalized level, or conversely, that current earnings are depressed relative to expected future performance. The price-to-book ratio is negative at -3.95, which indicates that the market values the company's intangible assets, such as its intellectual property and pipeline, far above its net book value, effectively ignoring the accounting value of its tangible assets. Alternative valuation metrics include a price-to-sales ratio of 1.91 and an EV/EBITDA of 23.08, which suggest the market is willing to pay a premium for the company's revenue stream and cash generation potential relative to its enterprise value. The stock has traded between a 52-week low of $3.03 and a 52-week high of $11.85. Based on the available data points, the current valuation context must be interpreted against this volatility range, where the high P/E suggests the price is positioned significantly above the 52-week low but the forward P/E indicates expectations of a move toward the upper end of the historical range if earnings materialize. The beta value of 0.25 indicates that the stock price exhibits low volatility relative to the broader market, moving with significantly less intensity than the overall index, which offers a distinct risk profile compared to typical large-cap equities.

Growth & Income

Revenue growth year-over-year is 10.1%, while earnings growth year-over-year is not available. The absence of a reported earnings growth figure precludes a direct comparison of growth rates, but the positive revenue growth indicates an expanding top line driven by the commercialization of its biosimilar portfolio. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it reinvests all generated earnings back into the business for research, development, and manufacturing capacity expansion rather than distributing income to shareholders. The company's financial profile is characterized by consistent revenue expansion without reliance on shareholder distributions, prioritizing long-term product development and market penetration over immediate income generation. This growth-oriented strategy is typical for companies in the Drug Manufacturers - Specialty & Generic sector that are still scaling their commercial operations and managing a pipeline of assets. The overall growth and income profile reflects a capital allocation strategy focused entirely on reinvestment, utilizing the free cash flow of $24.60M to support operational growth and potentially reduce the substantial debt load of $1.45B over time.